🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

140 results for “car-t” Clear

  1. GLPG CAR T-cell therapy

    Lakefront Biotherapeutics NV

    Hematological Malignancies

    phase 3 gene therapy active

    1 trial

  2. A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

    The George Institute

    Patients with HER2Positive Advanced Breast Cancer

    phase 2 other active

    1 trial

  3. AUTO CAR T cell therapy

    Autolus GmbH

    Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

    phase 2 mab active

    1 trial

  4. AUTO3 (CD19/22 CAR T cells

    Autolus GmbH

    B Acute Lymphoblastic Leukemia

    phase 2 mab completed

    1 trial

  5. Anti-BCMA-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  6. Anti-CD19 CAR-T

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia ,Lymphomas

    phase 2 mab active

    1 trial

  7. Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  8. Anti-CD20-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  9. Anti-CD30-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leukemia

    phase 2 mab active

    1 trial

  10. Anti-GPRC5D CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma in Relapse

    phase 2 mab active

    1 trial

  11. Anti-HER2 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 mab terminated

    1 trial

  12. Anti-LeY-CAR-transduced T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myeloid Malignancies

    phase 2 mab active

    1 trial

  13. Autologous BCMA-targeting CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma in Relapse

    phase 2 mab active

    1 trial

  14. Autologous CD5 CAR T-cells

    The First People's Hospital of Lianyungang

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  15. Autologous CD5 CAR T-cells

    Universal Integrated

    T-Cell Acute Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  16. Autologous CD7 CAR T-cell

    Universal Integrated

    T-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  17. Autologous hematopoietic stem cell infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prolonged Cytopenia Following CAR-T Therapy

    phase 2 mab active

    1 trial

  18. BCMA CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma, Plasma Cell Leukemia

    phase 2 mab active

    1 trial

  19. BCMA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    2 trials

  20. BCMA targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    1 trial

  21. Bispecific antibody-based combined with CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  22. CAR T-cell therapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia With Failed Remission

    phase 2 mab active

    1 trial

  23. CAR-T

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Chronic, B-Cell

    phase 2 mab active

    1 trial

  24. CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance

    Daihong Liu

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources